- Protracted attempts to alleviate a shortage of Johnson & Johnson's (JNJ +0.7%) Doxil have come up short because new manufacturers can't get regulatory approval for production until H2 2014, the company says.
- JNJ's lawyers have filed suit in an effort to force Boehringer Ingelheim to help settle the dispute which began in 2011 when the FDA shut down production at Boehringer's Ohio plant due to quality concerns.
- For now, the availability of the drug remains uncertain.
Doxil may remain scarce amid J&J, Boehringer dispute
Oct 1 2013, 13:49 ET